James Black Foundation Limited

Ian Duncan Linney

Sarkis Barret Kalindjian

Iain Mair McDonald

Michael John Pether

Ildiko Maria Buck

Matthew John Tozer

Nigel Paul Shankley

Elaine Anne Harper

Gillian Fairfull Watt

Caroline M Low

Paul Wright

David John Dunstone

James Black

Caroline Minli Rachel Low

Katherine Isobel Steel

Katherine Isobel Mary Steel

Tracey Cooke

Sonia Patricia Roberts

Martin Keith Walker

Elliot James Lilley

David Andrew Sykes

Eric Peter Griffin

Laurence Wright

Katherine Isabel Mary Steel

John David Gaffen

Robert Antony David Hull

Jeremy Gilbert Vinter

Compounds of the formula (I) or (II) and their pharmaceutically acceptable salts are ligands at gastrin and/or chole-cystokinin receptors n is from 1 to 4; Ris Cto Chydrocarbyl wherein up to two C atoms may optionally be replaced by N, O and/or S atoms and up to three H atoms may optionally be replaced by halogen atoms; Z is &#x2014;(NR)&#x2014;CO&#x2014;(NR)-(wherein a is 0 or 1, b is 0 or 1, and Rand Rare independently selected from H, Me, Et, Pr, Bn), &#x2014;CO&#x2014;NR&#x2014;CH&#x2014;CO&#x2014;NR&#x2014;, &#x2014;CO&#x2014;O&#x2014;, &#x2014;CH&#x2014;CH&#x2014;, &#x2014;CH&#x2550;CH&#x2014;, CH&#x2014;NR&#x2014; or a bond; Q is RV, or(a) wherein Ris &#x2014;CH&#x2014;; &#x2014;CH&#x2014;; or(b) Rand R, together with the nitrogen atom to which Ris attached, form a piperidine or pyrrolidine ring which is substituted by V; V is &#x2014;CO&#x2014;NH&#x2014;SO-Ph, &#x2014;SO&#x2014;NH&#x2014;CO-Ph, CHOH, or a group of the formula &#x2014;RU, (wherein U is &#x2014;COOH, tetrazolyl, &#x2014;CONHOH&#x2014; or &#x2014;SOH; and Ris a bond; Cto Chydrocarbylene, optionally substituted by hydroxy, amino or acetamino; &#x2014;O&#x2014;(Cto Calkylene)-; &#x2014;SONR&#x2014;CHR&#x2014;; &#x2014;CO&#x2014;NR&#x2014;CHR&#x2014;, Rand Rbeing independently selected from H and methyl; or &#x2014;NH&#x2014;(CO)&#x2014;CH&#x2014;, c being 0 or 1); m is 1 or 2; q is from 0 to 2, with the proviso that q is 1 or 2 when Z is a bond); Compositions comprising a compound of formula (I) or (II) are also described.

Gastrin and cholecystokinin receptor lignads (iv)

Compounds of formula (I) (and pharmaceutically acceptable salts thereof) are histamine Hreceptor ligands. A in the formula represents (CH), m being from 1 to 3; B is (CH), n being from 1 to 3; x is from 0 to 2; Ris Cto Chydrocarbyl, in which up to 2 carbon atoms may be replaced by O, S or N; and up to 2 hydrogen atoms may be replaced by halogen; Ris H or Cto Chydrocarbyl, in which up to 3 carbon atoms may be replaced by O, S or N, and up to 3 hydrogen atoms may be replaced by halogen; Ris absent when &#x2014;Y&#x2014;Z&#x2014;Ris attached to W, or is H or Cto Chydrocarbyl when &#x2014;Y&#x2014;Z&#x2014;Ris not attached to W; W is nitrogen; X is &#x2014;CH&#x2014;, &#x2014;O&#x2014; or &#x2014;NR&#x2014;, Rbeing H or Cto Calkyl; Y replaces a hydrogen atom on any of A, B, W and X, and is Cto Calkylene, in which one non-terminal carbon atom may be replaced by O; and Z is (II), (III), (IV), (V), (VI), or (VII) wherein R, Rand Rare independently H or Cto Chydrocarbyl, in which up to 3 carbon atoms may be replaced by O or N, and up to 3 hydrogen atoms may be replaced by halogen, and Q is H or methyl, or Q is linked to Ror Rto form a five-membered ring or Q is linked to Rto form a six-membered ring

Histamine H3 receptor ligands

Gastrin and cholecystokinin receptor ligands

1H-4(5)-substituted imidazole derivatives, their preparation and their use as histamine H3 receptor ligands

Benzodiazonine derivatives binding to cholecystokinin or gastrin

Growing community of inventors

London, United Kingdom

Ian Duncan Linney